Symbiotec Pharmalab Board Meeting on Nov 5 to Approve Q2 Results

Symbiotec Pharmalab Ltd has announced that its Board of Directors will convene on November 5, 2026. The primary agenda item is the consideration and approval of the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026, along with the limited review report. The trading window for designated persons and their immediate relatives will remain closed until 48 hours after the declaration of these financial results. Further details are available on the company's website.